<DOC>
	<DOCNO>NCT00005823</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . It yet know strong dos chemotherapy give long period time well tolerate effective less intensive chemotherapy . PURPOSE : This randomized phase III trial study intensive regimen chemotherapy see well work compare nonintensive regimen chemotherapy treat old patient acute myeloid leukemia myelodysplastic syndrome .</brief_summary>
	<brief_title>Intensive Compared With Nonintensive Chemotherapy Treating Older Patients With Acute Myeloid Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - Compare response rate , survival , quality life , supportive care requirement intensive versus nonintensive chemotherapy old patient acute myeloid leukemia high risk myelodysplastic syndrome . - Compare response achievement , response duration , survival , toxicity supportive care requirement differ dos daunorubicin cytarabine patient receive intensive chemotherapy . - Determine efficacy PSC 833 enhance effect daunorubicin patient receive intensive chemotherapy . - Compare relapse rate , death complete remission , disease free survival , survival short versus long intensive chemotherapy patient . - Compare response achievement , response duration , survival , toxicity , quality life , resource use hydroxyurea versus cytarabine patient receive low dose chemotherapy . - Determine response achievement , response duration , survival , toxicity , quality life , supportive care requirement addition tretinoin nonintensive chemotherapy patient . - Assess correlation P-gp BCL-2 family member treatment outcomes prognostic factor patient treatment regimen . OUTLINE : This randomize , multicenter study . Patients randomize electively assign either intensive nonintensive chemotherapy* . Intensive chemotherapy - Induction therapy : Patients randomize 1 6 treatment arm . Patients receive 2 course chemotherapy comprise 1 2 daunorubicin dos , 1 2 cytarabine dos , thioguanine , without PSC 833 . Patients receive daunorubicin IV daily day 1-3 cytarabine IV twice daily oral thioguanine daily day 1-10 course 1 . Treatment repeat approximately 31 day course 1 except cytarabine thioguanine give day 1-8 . - Arm I : Patients receive high dose daunorubicin , low dose cytarabine , thioguanine . - Arm II : Patients receive high dose daunorubicin , high dose cytarabine , thioguanine . - Arm III : Patients receive low dose daunorubicin , low dose cytarabine , thioguanine . - Arm IV : Patients receive low dose daunorubicin , high dose cytarabine , thioguanine . - Arm V : Patients receive treatment arm III combination continuous infusion PSC 833 begin day 1 . - Arm VI : Patients receive treatment arm IV combination continuous infusion PSC 833 begin day 1 . Patients refractory disease first course induction chemotherapy may continue intensive protocol arm enter nonintensive arm* . Patients achieve complete remission completion induction chemotherapy remove study . Patients complete remission induction therapy receive consolidation therapy . - Consolidation therapy : Patients complete remission induction randomize either short long consolidation . - Short consolidation : Patients receive mitoxantrone IV day 1-3 cytarabine IV 2 hour twice daily day 1-3 . - Long consolidation : Patients complete short consolidation receive idarubicin IV 5 minute daily day 1 3 , cytarabine IV 2 hour twice daily etoposide IV 1 hour daily day 1-3 . Non-intensive chemotherapy* - Patients randomize 1 4 treatment arm . - Arm I : Patients receive oral hydroxyurea necessary control WBC count treatment failure . - Arm II : Patients receive hydroxyurea arm I oral tretinoin daily 16 week . - Arm III : Patients receive low dose cytarabine subcutaneously twice daily day 1-10 every 28 day minimum 4 course . - Arm IV : Patients receive cytarabine arm III plus oral tretinoin daily 16 week . NOTE : *Patients liver function test &gt; 2 time upper limit normal eligible nonintensive randomization Quality life assess study entry , 1 , 3 , 6 month . Patients follow one year . PROJECTED ACCRUAL : Approximately 2,000 patient ( 1,200 intensive arm 800 nonintensive arm ) accrue study 5 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Acute myeloid leukemia ( de novo secondary ) OR Myelodysplastic syndrome More 10 % myeloblast bone marrow Refractory anemia excess blast Refractory anemia excess blast transformation Chronic myelomonocytic leukemia No acute promyelocytic leukemia ( FAB type M3 ) No blastic phase chronic myeloid leukemia PATIENT CHARACTERISTICS : Age : 60 ( young patient allow intensive chemotherapy indicate ) Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : No liver function test â‰¥ 2 time normal ( nonintensive therapy arm ) Renal : Not specify Cardiovascular : No myocardial infarction within past 6 month patient receive daunorubicin PSC 833 Other : No concurrent active malignancy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior cytotoxic chemotherapy leukemia Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
</DOC>